We produce patient-specific 3D organoids at scale to determine the best cancer patients for new drugs. As of today, just 3% of oncology drugs will go from Phase I clinical trials to on-market. Among the most common reasons for drug failure is lack of proven efficacy in the target population. Traditional biomarkers do improve outcomes in select cases, but more often cannot discriminate between responders and non-responders.
Our platform determines how cancer patients will respond to drug treatments. We use functional outcomes of patient tissue in conjunction with genomic, proteomic, and immune profiling data. We are able to determine which patient subpopulations will respond best to new drugs and further, understand why.
Through in-licensing and partnership, Known Medicine is developing drugs with the ability to determine the best patients for each discovered drug.